Home/Sionna Therapeutics/Dr. Jennifer L. Grootenhuis
DJ

Dr. Jennifer L. Grootenhuis

Chief Scientific Officer

Sionna Therapeutics

Therapeutic Areas

Sionna Therapeutics Pipeline

DrugIndicationPhase
SION-638Cystic Fibrosis (F508del mutation)Phase 1
SION-109Cystic Fibrosis (F508del mutation)Preclinical
SION-451Cystic Fibrosis (F508del mutation)Preclinical
SION-676Cystic Fibrosis (F508del mutation)Preclinical